Arcutis jumps after Mizuho highlights ‘robust’ weekly script growth

Mizuho says that for the week ending August 16, Arcutis Biotherapeutics’ Zoryve franchise had “robust” week-over-week script growth, with prescriptions growing 17.2% according to the firm’s psoriasis topicals scripts tracker. All three products experienced double-digit week-over-week growth, the analyst tells investors in a research note. “This strong growth should help mitigate recent concerns,” contends Mizuho. Shares of Arcutis are up 20%, or $1.65, to $9.98 following Mizuho’s research report.